{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:57:13Z","timestamp":1769839033277,"version":"3.49.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"35","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1097\/md.0000000000004481","type":"journal-article","created":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T22:42:55Z","timestamp":1472683375000},"page":"e4481","source":"Crossref","is-referenced-by-count":12,"title":["Comparative persistence of antiepileptic drugs in patients with epilepsy"],"prefix":"10.1097","volume":"95","author":[{"given":"Edward Chia-Cheng","family":"Lai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Yang","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Chou","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yea-Huei Kao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin-Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swu-Jane","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soko","family":"Setoguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-17-20210226","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1474-4422(11)70047-3","article-title":"The pharmacological treatment of epilepsy in adults","volume":"10","author":"Perucca","year":"2011","journal-title":"Lancet Neurol"},{"key":"R2-17-20210226","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1136\/bmj.e345","article-title":"Newer drugs for focal epilepsy in adults","volume":"344","author":"Brodie","year":"2012","journal-title":"BMJ"},{"key":"R3-17-20210226","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1528-1167.2006.00585.x","article-title":"ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"47","author":"Glauser","year":"2006","journal-title":"Epilepsia"},{"key":"R4-17-20210226","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"R5-17-20210226","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"R6-17-20210226","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"key":"R7-17-20210226","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1528-1157.1998.tb01167.x","article-title":"Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy","volume":"39","author":"Chadwick","year":"1998","journal-title":"Epilepsia"},{"key":"R8-17-20210226","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/schbul\/sbs002","article-title":"Effectiveness of sulpiride in adult patients with schizophrenia","volume":"39","author":"Lai","year":"2013","journal-title":"Schizophr Bull"},{"key":"R9-17-20210226","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"R10-17-20210226","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/jamaneurol.2014.808","article-title":"Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action","volume":"71","author":"Margolis","year":"2014","journal-title":"JAMA Neurol"},{"key":"R11-17-20210226","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1081\/DMR-120023681","article-title":"PM frequencies of major CYPs in Asians and Caucasians","volume":"35","author":"Mizutani","year":"2003","journal-title":"Drug Metab Rev"},{"key":"R12-17-20210226","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1081\/DMR-28805","article-title":"An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore","volume":"37","author":"Chowbay","year":"2005","journal-title":"Drug Metab Rev"},{"key":"R13-17-20210226","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1212\/WNL.63.10_suppl_4.S3","article-title":"Pharmacogenetics and enzyme induction\/inhibition properties of antiepileptic drugs","volume":"63","author":"Anderson","year":"2004","journal-title":"Neurology"},{"key":"R14-17-20210226","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jama.2014.7859","article-title":"Genetic variants associated with phenytoin-related severe cutaneous adverse reactions","volume":"312","author":"Chung","year":"2014","journal-title":"JAMA"},{"key":"R15-17-20210226","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1517\/17425255.2015.1053463","article-title":"CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects","volume":"11","author":"Franco","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R16-17-20210226","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2741\/713","article-title":"Genetic polymorphisms associated with antiepileptic metabolism","volume":"6","author":"Lopez-Garcia","year":"2014","journal-title":"Front Biosci"},{"key":"R18-17-20210226","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1053\/j.gastro.2010.06.067","article-title":"Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel","volume":"139","author":"Wu","year":"2010","journal-title":"Gastroenterology"},{"key":"R19-17-20210226","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1528-1167.2011.03332.x","article-title":"Geographic variation in the age- and gender-specific prevalence and incidence of epilepsy: analysis of Taiwanese National Health Insurance-based data","volume":"53","author":"Chen","year":"2012","journal-title":"Epilepsia"},{"key":"R20-17-20210226","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jfma.2013.09.009","article-title":"Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database","volume":"114","author":"Hsieh","year":"2015","journal-title":"J Formos Med Assoc"},{"key":"R21-17-20210226","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1111\/ijs.12380","article-title":"Identifying renal dysfunction in stroke patients using diagnostic codes in the Taiwan National Health Insurance Research Database","volume":"10","author":"Hsieh","year":"2015","journal-title":"Int J Stroke"},{"key":"R22-17-20210226","doi-asserted-by":"crossref","first-page":"500","DOI":"10.2188\/jea.JE20140076","article-title":"Validation of acute myocardial infarction cases in the national health insurance research database in taiwan","volume":"24","author":"Cheng","year":"2014","journal-title":"J Epidemiol"},{"key":"R23-17-20210226","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eplepsyres.2011.05.003","article-title":"Trends in the use of antiepileptic drugs in Taiwan from 2003 to 2007: a population-based national health insurance study","volume":"96","author":"Hsieh","year":"2011","journal-title":"Epilepsy Res"},{"key":"R24-17-20210226","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1528-1167.2012.03693.x","article-title":"Comparative stroke risk of antiepileptic drugs in patients with epilepsy","volume":"54","author":"Hsieh","year":"2013","journal-title":"Epilepsia"},{"key":"R25-17-20210226","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.psychres.2006.02.006","article-title":"Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics","volume":"144","author":"Gianfrancesco","year":"2006","journal-title":"Psychiatry Res"},{"key":"R26-17-20210226","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1528-1167.2009.02235.x","article-title":"Should enzyme-inducing antiepileptic drugs be considered first-line agents?","volume":"50","author":"Mintzer","year":"2009","journal-title":"Epilepsia"},{"key":"R27-17-20210226","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/pds.2186","article-title":"Effects of epilepsy and selected antiepileptic drugs on risk of myocardial infarction, stroke, and death in patients with or without previous stroke: a nationwide cohort study","volume":"20","author":"Olesen","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R28-17-20210226","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.seizure.2012.04.014","article-title":"Trends in antiepileptic drug utilisation in UK primary care 1993-2008: cohort study using the General Practice Research Database","volume":"21","author":"Nicholas","year":"2012","journal-title":"Seizure"},{"key":"R30-17-20210226","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","article-title":"High-dimensional propensity score adjustment in studies of treatment effects using health care claims data","volume":"20","author":"Schneeweiss","year":"2009","journal-title":"Epidemiology"},{"key":"R31-17-20210226","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1097\/MLR.0b013e31806518ac","article-title":"Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases","volume":"45","author":"Curtis","year":"2007","journal-title":"Med Care"},{"key":"R32-17-20210226","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/1471-2288-13-142","article-title":"Effects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical example","volume":"13","author":"Le","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"R33-17-20210226","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/pds.1062","article-title":"An application of propensity score matching using claims data","volume":"14","author":"Seeger","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R35-17-20210226","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1212\/WNL.60.11_suppl_4.S2","article-title":"Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy","volume":"60","author":"Kwan","year":"2003","journal-title":"Neurology"},{"key":"R36-17-20210226","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/j.1528-1167.2011.03047.x","article-title":"Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis","volume":"52","author":"Costa","year":"2011","journal-title":"Epilepsia"},{"key":"R37-17-20210226","first-page":"1062","article-title":"Gabapentin: an update of its pharmacological properties and therapeutic use in epilepsy","volume":"16","author":"Honarmand","year":"2011","journal-title":"J Res Med Sci"},{"key":"R38-17-20210226","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.eplepsyres.2008.11.018","article-title":"Antiepileptic drug utilization in Taiwan: analysis of prescription using National Health Insurance database","volume":"84","author":"Hsieh","year":"2009","journal-title":"Epilepsy Res"},{"key":"R39-17-20210226","first-page":"5","article-title":"Real-world persistence and treatment failure associated with first line use of antiepileptic drug treatment in a large US","volume":"82","author":"Divino","year":"2014","journal-title":"Manag Care Popul Neurol"},{"key":"R40-17-20210226","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.yebeh.2015.08.014","article-title":"Comparative effectiveness of generic versus brand-name antiepileptic medications","volume":"52","author":"Gagne","year":"2015","journal-title":"Epilepsy Behav"},{"key":"R41-17-20210226","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1111\/ene.12766","article-title":"Efficacy of phenytoin, valproic acid, carbamazepine and new antiepileptic drugs on control of late-onset post-stroke epilepsy in Taiwan","volume":"22","author":"Huang","year":"2015","journal-title":"Eur J Neurol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000004481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:30:43Z","timestamp":1620959443000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201608300-00017"}},"subtitle":["A STROBE-compliant retrospective cohort study"],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":38,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000004481","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}